. Author manuscript; available in PMC: 2023 Jan 1.

Published in final edited form as: Alzheimer Dis Assoc Disord. 2022 Jan-Mar;36(1):64–72. doi: 10.1097/WAD.0000000000000473

Table 4.

Additional scales used as primary or secondary outcomes in DLB clinical trials

Outcome Measure Category	Scale	Primary outcome frequency	Ref.	Secondary outcome frequency	Ref.
ADL	UPDRS Part II	1	³⁵	6	^{11,34,47,48,59,65}
	ADCS-ADL23	0	N/A	3	^24,49,65
Caregiver burden	ZBI	2	^10,17	5	^{15,24,40,53,60}
	NPI caregiver distress score	0	N/A	2	^13,63
	Relative stress scale	0	N/A	2	^59,61
Motor symptoms	UPDRS-III	11	^{10,13,14,21,26,30,31,35,37,53}	12	^{11,18,24,25,32,34,47,48,52,59,63,65}
	TUG	0	N/A	4	^47,58,65,67
Sleepiness	ESS	2	^33,43	2	^18,66

ADL: Activities of Daily Living, UPDRS: Unified Parkinson’s Disease Rating Scale, ADCS-ADL23: Alzheimer’s Disease. Cooperative Study-Activities of Daily. Living, ZBI: Zarit Burden Interview, NPI: Neuropsychiatric Inventory, TUG: Timed up and go, ESS: Epworth Sleepiness Scale